Dear followers, the BSMO account is now moving to... 𝐋𝐢𝐧𝐤𝐞𝐝𝐈𝐧! Please follow us on our LinkedIn page for new informations 😊

❗ Two weeks left to apply! Older adults make up most patients with #cancer, yet evidence does not fully reflect them. In #GeriatricOncology, better research starts with better study design. Join the #SIOGResearchMasterclass. Apply by 8 March: loom.ly/QFO3xsk #GeriOnc

Starting the week with a conference at @sciensano with many stakeholders involved in the field of genomics. Discussions will include perspectives on future directions and data governance. I will be presenting the PRECISION program led by the @mybsmo 1/3

Published in @JCOOP_ASCO #ASCO Guideline Update for #adjuvant CDK4/6 inhibitors The panel recommends: 🟢Abemaciclib in pts with concordant high-risk btw monarchE and NATALEE 🟠Conditional strength of recommendation for ribociclib among pts with NATALEE criteria only @OncoAlert

Now available in @Nature_NPJ Precision Oncology, results from the BALLETT molecular profiling study 🧬 🎯 using CGP & a national 🇧🇪 molecular tumor board. BALLETT is part of the @mybsmo PRECION program. 👏 Brigitte Maes & Pieter-Jan Volders @sciensano nature.com/articles/s41698-0…

𝐂𝐨𝐥𝐨𝐫𝐞𝐜𝐭𝐚𝐥 𝐜𝐚𝐧𝐜𝐞𝐫 is the 3rd most frequent cancer in Belgium with almost 8.000 new cases per year. Screening is recommended from the age of 50 💩 Think about it 🤓

📣 Updated ESMO #ClinicalPracticeGuideline on #HepatocellularCarcinoma includes new treatment strategies in early- and intermediate-stage disease and evolving options for systemic therapy. #HCC #GastrointestinalCancers #ESMOGuidelines 🔗 ow.ly/hrhH50V2GiU

📣 Join us in 📍Barcelona for #ESMOGI25, 2–5 July 2025. ⏰ Early registration deadline: 16 April Don't miss this leading congress in GI oncology! Connect with top experts and explore the latest in research and treatment. 👉 Register today! 🔗 ow.ly/GW9x50V1Y6t

Abstract submission now open for #ESMO25 in #BERLIN! We have a fantastic educational programme in place, and now it's time for the scientific programme. Looking forward to your abstracts! Deadline: May13th esmo.org/meeting-calendar/es… @DrChoueiri @myESMO @DrChoueiri @FAndreMD

Our young residents spent the day at the UZ VUB to learn everything about 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐌𝐞𝐭𝐡𝐨𝐝𝐨𝐥𝐨𝐠𝐲 with Dr. Ahmad Awada and then they dived into the world of 𝐍𝐞𝐮𝐫𝐨-𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 with Dr. Bart Neyns 🤓😇 @mybsmo

t is our pleasure to invite you for the @mybsmo Webinar on Toxicity management with ADCs in solid tumours. When 24 April 2025 Time 7-8.15 pm More information and registration at: bsmo.be/bsmo-webinar-on-toxi…

Great SIOG collaboration on this important topic. Management of immune checkpoint inhibitor-associated toxicities in older adults with cancer: recommendations from the International Society of Geriatric Oncology (SIOG) - The Lancet Oncology thelancet.com/journals/lanon…

Day One #OncoAlertColloquium 🚨REGISTER for FREE HERE👉 buff.ly/4aGKulG @VincentWenxinXu 🇺🇸 of @DanaFarberNews Doing #KidneyCancer in Review REGISTER NOW for a Live chat with Dr. Xu A summation from Dr. Xu "Several important clinical updates in 2024 have changed the way that we treat renal cell carcinoma. First, in the post-surgery setting, the KEYNOTE-564 trial showed that adjuvant pembrolizumab improves not only disease-free survival but also overall survival. Adjuvant pembrolizumab is now a standard of care among eligible patients with clear cell renal cell carcinoma. Second, the TiNivo-2 trial has confirmed, among patients with advanced RCC and who had progression after prior immunotherapy, that rechallenge with tivozanib plus nivolumab is no better than tivozanib alone. This is consistent with prior data from CONTACT-03 and suggests that rechallenge with anti-PD-1 or PD-L1 should be discouraged in RCC. Third, based on CheckMate 67T, subcutaneous nivolumab is now FDA approved as an alternative to IV nivolumab. Fourth, the SUNNIFORECAST trial demonstrated that among patients with divergent histology RCC, nivolumab plus ipilimumab can be an effective treatment option. More results are eagerly anticipated in 2025 and several ongoing trials may continue to change the standard of care in the near future." GU Faculty @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @cdanicas @DrYukselUrun @seanmmcbride #OncoAlertAF @nataliagandur @acampsmalea @BiagioRicciutMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK

🙏 Thanks for the appreciation @matteolambe and @StrijbosMichiel We can confirm you have good taste 👌☺️

Me too, it’s super nice!

It has been a pleasure to present the results of our translational research project on #lobular breast cancer awarded with a @GileadSciences grant at #BSMO25 in the beautiful Bruges🇧🇪 Thanks to @E_de_Azambuja and all amazing colleagues & friends @JulesBordet @mybsmo @OncoAlert

Love the new @mybsmo logo!!

Brilliant talk by Prof Martine Piccart on the evolution of #clinicaltrials & #translationalresearch in #oncology over the last decades 🚨 In order to serve our patients, #academia has to evolve fast & come out with innovative & collaborative strategies! #BSMO25 @mybsmo @OncoAlert

Always so special being back in 🇧🇪 with many friends I have the lucky to keep collaborating with in many different academic #BreastCancer projects…thanks a lot @E_de_Azambuja @kevinpunie and @mybsmo for having me in beautiful Bruges ❤️🤩 @OncoAlert @UniGenova @SanMartino_Ge

Professeur Martine Piccart is opening the Young Oncologist Session at the 27th annual meeting @mybsmo. Her wonderful experience in clinical studies will help young oncologists to imagine their own! 🤗✍️